ID   Karpas-45
AC   CVCL_1326
SY   KARPAS-45; Karpas 45; KARPAS 45; KARPAS45; K45; T-45; T45; Line 45
DR   CLO; CLO_0007067
DR   CLDB; cl35
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473409
DR   cancercelllines; CVCL_1326
DR   Cell_Model_Passport; SIDM01007
DR   ChEMBL-Cells; CHEMBL3308305
DR   ChEMBL-Targets; CHEMBL2366305
DR   Cosmic; 907272
DR   Cosmic; 913413
DR   Cosmic; 1012075
DR   Cosmic; 1151781
DR   Cosmic; 1175130
DR   Cosmic; 1191704
DR   Cosmic; 1281370
DR   Cosmic; 1330505
DR   Cosmic; 1524799
DR   Cosmic; 1664523
DR   Cosmic; 1760525
DR   Cosmic; 2165714
DR   Cosmic; 2391812
DR   Cosmic; 2602917
DR   Cosmic-CLP; 907272
DR   DepMap; ACH-002256
DR   DSMZ; ACC-105
DR   DSMZCellDive; ACC-105
DR   ECACC; 06072602
DR   EGA; EGAS00001000978
DR   GDSC; 907272
DR   GEO; GSM1669977
DR   GEO; GSM5137719
DR   IARC_TP53; 27173
DR   LINCS_LDP; LCL-1015
DR   NCBI_Iran; C180
DR   PharmacoDB; KARPAS45_731_2019
DR   PRIDE; PXD023662
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1326
DR   Wikidata; Q54899501
RX   DOI=10.1007/978-1-4613-2823-0_29;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   DOI=10.1016/0145-2126(77)90063-7;
RX   PubMed=3264071;
RX   PubMed=9933131;
RX   PubMed=14671638;
RX   PubMed=15472075;
RX   PubMed=15843827;
RX   PubMed=16408098;
RX   PubMed=17170727;
RX   PubMed=20164919;
RX   PubMed=22675565;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35354797;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: 50-100 hours (ECACC=06072602).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Microsatellite instability: Instable (MSI) (PubMed=31068700).
CC   Sequence variation: Gene fusion; HGNC; 7139; FOXO4 + HGNC; 7132; KMT2A; Name(s)=KMT2A-FOXO4, MLL-MLLT7; MLL-AFX1 (PubMed=14671638; PubMed=15843827).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Val2194Ala (c.6581T>C); ClinVar=VCV000565658; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Ala586Gly (c.1757C>G); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 3495; ETV6; Simple; p.His328Tyr (c.982C>T); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 3689; FGFR2; Simple; p.Met584Arg (c.1751T>G) (p.Met585Arg, c.1754T>G); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Arg962His (c.2885G>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp131Asn (c.391G>A); ClinVar=VCV000409719; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Ala48Thr (c.142G>A); ClinVar=VCV000454188; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Glu157Gly (c.470A>G); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Gly221Val (c.662G>T); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gln2459Ter (c.7375C>T); Zygosity=Heterozygous (PubMed=15472075).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Asp1852Asn (c.5554G>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Val2045Ile (c.6133G>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 8804; PDGFRB; Simple; p.His277Gln (c.831C>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Asn879Ser (c.2636A>G); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Asn288Lys (c.864C>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg394Gln (c.1181G>A) (p.Arg467Gln, c.1400G>A); ClinVar=VCV000419332; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.06%; Native American=0.47%; East Asian, North=0.03%; East Asian, South=0%; South Asian=2.75%; European, North=68.54%; European, South=28.16% (PubMed=30894373).
CC   Discontinued: DSMZ; ACC-105; true.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 11,14
ST   D13S317: 9,14
ST   D16S539: 9,13
ST   D18S51: 16,18
ST   D19S433: 14
ST   D21S11: 30,31.2
ST   D2S1338: 17,26
ST   D3S1358: 14,15
ST   D5S818: 11,12
ST   D7S820: 8,11
ST   D8S1179: 11,15
ST   FGA: 22,23
ST   Penta D: 12,13
ST   Penta E: 5,10
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 14,18
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   2Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 41
//
RX   DOI=10.1007/978-1-4613-2823-0_29;
RA   Karpas A.;
RT   "Viruses and human leukemia in vitro.";
RL   (In) Human leukemia. Cytochemical and ultrastructural techniques in diagnosis and research. Developments in Oncology, Vol. 14; Polliack A. (eds.); pp.495-526; Martinus Nijhoff Publishing; Boston (1984).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   DOI=10.1016/0145-2126(77)90063-7;
RA   Karpas A., Hayhoe F.G.J., Greenberger J.S., Barker C.R., Cawley J.C.,
RA   Lowenthal R.M., Moloney W.C.;
RT   "The establishment and cytological, cytochemical and immunological
RT   characterisation of human haemic cell lines: evidence for
RT   heterogeneity.";
RL   Leuk. Res. 1:35-49(1977).
//
RX   PubMed=3264071; DOI=10.1073/pnas.85.23.9229;
RA   Karpas A., Fleet G.W.J., Dwek R.A., Petursson S., Namgoong S.K.,
RA   Ramsden N.G., Jacob G.S., Rademacher T.W.;
RT   "Aminosugar derivatives as potential anti-human immunodeficiency virus
RT   agents.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:9229-9233(1988).
//
RX   PubMed=9933131; DOI=10.1016/S0145-2126(98)00133-7;
RA   Burger R., Hansen-Hagge T.E., Drexler H.G., Gramatzki M.;
RT   "Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines:
RT   suggestion for classification by immunophenotype and T-cell receptor
RT   studies.";
RL   Leuk. Res. 23:19-27(1999).
//
RX   PubMed=14671638; DOI=10.1038/sj.leu.2403236;
RA   Drexler H.G., Quentmeier H., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   MLL gene alterations.";
RL   Leukemia 18:227-232(2004).
//
RX   PubMed=15472075; DOI=10.1126/science.1102160;
RA   Weng A.P., Ferrando A.A., Lee W., Morris J.P. IV, Silverman L.B.,
RA   Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.;
RT   "Activating mutations of NOTCH1 in human T cell acute lymphoblastic
RT   leukemia.";
RL   Science 306:269-271(2004).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=17170727; DOI=10.1038/sj.leu.2404486;
RA   Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M.,
RA   de Vos J., MacLeod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M.,
RA   Langerak A.W.;
RT   "Human T-cell lines with well-defined T-cell receptor gene
RT   rearrangements as controls for the BIOMED-2 multiplex polymerase chain
RT   reaction tubes.";
RL   Leukemia 21:230-237(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22675565; DOI=10.1371/journal.pone.0038463;
RA   Atak Z.K., De Keersmaecker K., Gianfelici V., Geerdens E.,
RA   Vandepoel R., Pauwels D., Porcu M., Lahortiga I., Brys V., Dirks W.G.,
RA   Quentmeier H., Cloos J., Cuppens H., Uyttebroeck A., Vandenberghe P.,
RA   Cools J., Aerts S.;
RT   "High accuracy mutation detection in leukemia on a selected panel of
RT   cancer genes.";
RL   PLoS ONE 7:E38463-E38463(2012).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//